Lundbeck and Solvay terminate antipsychotic bifeprunox over lack of efficacy
This article was originally published in Scrip
Executive Summary
Lundbeck and Solvay have ended the development of their new-generation atypical antipsychotic bifeprunox after reviewing data from an ongoing Phase III programme.